Evan Christopher Lam

This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.

QuickFit quantifies viral growth and fitness in vitro using high-throughput RT-qPCR, offering higher throughput and lower error than traditional methods.